Prothena Corporation

Prothena Corporation Employees

The The number of employees of Prothena Corporation (PRTA) as of Nov 17, 2026 is 67. In the previous year, The number of employees was 67.00 — a change of 0.00% (lower).

Employees

67

YoY

0.00%

Last updated:

In 2025, Prothena Corporation employed 67 people, a 0.00% change from the 67.00 number of employees in the previous year.

The Prothena Corporation Employees history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Employees
Date
Employees
Jan 1, 2018
67.00 USD
Jan 1, 2019
67.00 USD
Jan 1, 2020
67.00 USD
Jan 1, 2021
67.00 USD
Jan 1, 2022
67.00 USD
Jan 1, 2023
67.00 USD
Jan 1, 2024
67.00 USD
Jan 1, 2025
67.00 USD
The Prothena Corporation Employees history
YEAREmployeesYoY
670.00%
670.00%
670.00%
670.00%
670.00%
670.00%
670.00%
670.00%
670.00%
670.00%
670.00%
67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

Employees Details

Examining Prothena Corporation's Employee Base

Prothena Corporation's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Prothena Corporation's operational capacity and future potential.

Year-to-Year Comparison

Assessing Prothena Corporation's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Prothena Corporation's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Prothena Corporation’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Prothena Corporation stock

The number of employees of Prothena Corporation is 67 in 2025.

The number of employees of Prothena Corporation changed from 67.00 to 67, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of employees Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

The number of employees describes the number of people directly employed by the company.

The number of employees's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The number of employees's Prothena Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Prothena Corporation

All Key Metrics — Prothena Corporation